BioCardia, Inc. Common Stock
Symbol: BCDA (NASDAQ)
Company Description:
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
- Today's Open: $2.13
- Today's High: $2.275
- Today's Low: $2.061
- Today's Volume: 81.61K
- Yesterday Close: $2.12
- Yesterday High: $2.16
- Yesterday Low: $2.105
- Yesterday Volume: 34.38K
- Last Min Volume: 200
- Last Min High: $2.264
- Last Min Low: $2.261
- Last Min VWAP: $2.261
- Name: BioCardia, Inc. Common Stock
- Website: https://www.biocardia.com
- Listed Date: 1995-10-25
- Location: SUNNYVALE, CA
- Market Status: Active
- CIK Number: 0000925741
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $12.30M
- Round Lot: 100
- Outstanding Shares: 5.80M
- Asset Type: CS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-25 | 4 | View |
| 2025-08-13 | 4 | View |
| 2025-08-13 | SCHEDULE 13G/A | View |
| 2025-08-13 | 8-K | View |
| 2025-08-12 | 4 | View |
| 2025-08-11 | 4 | View |
| 2025-08-11 | 10-Q | View |
| 2025-08-11 | 8-K | View |
| 2025-08-04 | 8-K | View |
| 2025-07-24 | 8-K | View |
| 2025-07-17 | EFFECT | View |
| 2025-07-17 | EFFECT | View |
| 2025-07-16 | 8-K | View |
| 2025-07-15 | CORRESP | View |
| 2025-07-15 | CORRESP | View |
| 2025-07-14 | UPLOAD | View |
| 2025-07-09 | S-3 | View |
| 2025-07-08 | 424B5 | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |